• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

己酮可可碱治疗周围闭塞性血管疾病(作者译)

[Treatment of peripheral occlusive vascular disease with pentoxifylin (author's transl)].

作者信息

Traumann K J

出版信息

Med Klin. 1976 Mar 12;71(11):465-8.

PMID:1263995
Abstract

102 patients suffering from peripheral occlusive vascular disease were treated with Pentoxifylline (Trental) parenterally (i.v. infusions) and orally (dragees). Surprisingly good therapeutic response was obtained not only in patients stage II but also stage III (after Fontaine), in total 84% of the patients showing improvement. These favourable results can only be explained by increase of nutritious circulation indicating an improvement of blood-flow-properties in the microvasculature. The observed particular efficacy of Pentoxifylline necessitates a more differentiated valuation of the systemic (intravenous) administration of vasoactive drugs all the more so as the majority of patients with occlusive vascular disease are accessible to conservative treatment only.

摘要

102例外周闭塞性血管疾病患者接受了己酮可可碱(曲克芦丁)的肠外(静脉输注)和口服(糖衣丸)治疗。不仅II期患者,而且III期(根据Fontaine分期)患者都获得了令人惊讶的良好治疗反应,总共有84%的患者病情有所改善。这些良好结果只能通过营养循环的增加来解释,这表明微血管系统中血流特性得到了改善。己酮可可碱所观察到的特殊疗效使得有必要对血管活性药物的全身(静脉)给药进行更细致的评估,尤其是因为大多数闭塞性血管疾病患者只能接受保守治疗。

相似文献

1
[Treatment of peripheral occlusive vascular disease with pentoxifylin (author's transl)].己酮可可碱治疗周围闭塞性血管疾病(作者译)
Med Klin. 1976 Mar 12;71(11):465-8.
2
[Experiences with Trental in peripheral circulatory disorders and cerebrovascular insufficiency (author's transl)].
Munch Med Wochenschr. 1973 Oct 5;115(40):1745-9.
3
[Therapy of peripheral arterial circulation disorders using 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine (BL 191)].使用3,7 - 二甲基 - 1 -(5 - 氧代己基)黄嘌呤(BL 191)治疗外周动脉循环障碍
Arzneimittelforschung. 1973 Apr;23(4):571-3.
4
[Treatment of chronic arterial occlusive disease. Clinical study with a new galenic preparation of Pentoxifyllin (Trental 400) (author's transl)].
Med Klin. 1978 May 26;73(21):791-7.
5
Pentoxifylline (Trental)--a new drug for the treatment of peripheral chronic occlusive arterial disease.
J Med. 1988;19(2):89-107.
6
[Ophthalmological experiences with the xanthine compound BL 191 (author's transl)].[黄嘌呤化合物BL 191的眼科应用经验(作者译)]
Med Klin. 1973 Nov 23;68(47):1540-8.
7
[Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].前列环素与己酮可可碱治疗下肢周围动脉不可手术的闭塞症患者
Srp Arh Celok Lek. 1999 Jul-Aug;127(7-8):249-53.
8
[Value of vasoactive drugs in conservative therapy of peripheral arterial occlusive disease].[血管活性药物在周围动脉闭塞性疾病保守治疗中的价值]
Z Arztl Fortbild Qualitatssich. 1999 Nov;93(9):639-44.
9
[Treatment of chronic arterial circulatory disorders. Double blind trial with Trental 400 (author's transl)].[慢性动脉循环障碍的治疗。曲克芦丁400双盲试验(作者译)]
MMW Munch Med Wochenschr. 1976 Oct 22;118(43):1399-1402.
10
[Clinical trial of Trental 100 in patients with peripheral arterial occlusive diseases (author's transl)].
MMW Munch Med Wochenschr. 1977 Jul 1;119(26):901-4.